Skip to content

Effect of scalp nerve block combined with dexmedetomidine pump on postoperative recovery quality of patients with cerebral tumor

Effect of scalp nerve block combined with dexmedetomidine pump on postoperative recovery quality of patients with cerebral tumor

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062068
Enrollment
Unknown
Registered
2022-07-21
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral tumor anesthesia

Interventions

Blank control group (Group A) :Routine anaesthesia
Scalp nerve block group (group B) :After induction, scalp nerve block was performed with 0.5% ropivacaine under stable anesthesia
Dexmedetomidine group (group C):Dexmedetomidine was pumped at 1ug/kg for 10min before induction, continuously pumped at 0.4ug/kg during surgery, 0.8ug/Kg was pumped 40min before the end of surgery for
Dexmedetomidine combined with scalp nerve block group (group D) :Dexmedetomidine was pumped at 1ug/kg for 10min before induction, continuously pumped at 0.4ug/kg during surgery, 0.8ug/Kg was pumped 40

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients to be resected for supratentorial tumor (surgical path included frontal, temporal, apical and occipital paths); 2. ASA grade I-III; 3. Age >65 or <18 years; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Contraindications of scalp nerve block: abnormal coagulation function, infection of the puncture site, local anesthetic allergy, etc.; 2. Chronic pain or neuropathic pain, long-term use of painkillers for treatment; 3. Have a history of neurological or mental illness, and take sedative drugs for a long time; 4. Unable to cooperate with researchers for any reason: hearing impairment, language comprehension impairment, mental illness, etc.; 5. Cardiomyopathies or persistent arrhythmias such as permanent atrial fibrillation, sick sinus syndrome, atrioventricular block, sinus bradycardia, or other persistent supraventricular rhythm abnormalities; 6. Advanced hepatic and renal insufficiency; 7. Pregnant or lactating women; 8. For acute or chronic pain, take painkillers within 24 hours; 9. The patient refused to participate or had already participated in another investigation.

Design outcomes

Primary

MeasureTime frame
24 hours of postoperative quality of life recovery (QOR-40) score;

Secondary

MeasureTime frame
VAS scores for resting and exercise at 2h, 6h, 12h, 24h and 48h after extubation; First postoperative relief analgesia time, postoperative analgesia satisfaction 24 hours;Intraoperative traumatic event time, extubation MAP, HR;

Countries

China

Contacts

Public ContactChen Xiuxia
cxxlxy@sina.com+86 15205200798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026